Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Translate Bio participates in a conference call with SunTrust » 13:25
04/06/20
04/06
13:25
04/06/20
13:25
TBIO

Translate Bio

$10.23 /

+0.7 (+7.35%)

Biotech Analyst Joon Lee…

Biotech Analyst Joon Lee holds a conference call with CFO Schroer, CTO DeRosa and VP Dahlman on April 6 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
TBIO Translate Bio
$10.23 /

+0.7 (+7.35%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Conference/Events
Translate Bio participates in a conference call with SunTrust » 04:55
04/06/20
04/06
04:55
04/06/20
04:55
TBIO

Translate Bio

$9.53 /

+0.5 (+5.54%)

Biotech Analyst Joon Lee…

Biotech Analyst Joon Lee holds a conference call with CFO Schroer, CTO DeRosa and VP Dahlman on April 6 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
TBIO Translate Bio
$9.53 /

+0.5 (+5.54%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Conference/Events
Translate Bio participates in a conference call with SunTrust » 12:35
04/03/20
04/03
12:35
04/03/20
12:35
TBIO

Translate Bio

$8.89 /

-0.14 (-1.55%)

Biotech Analyst Joon Lee…

Biotech Analyst Joon Lee holds a conference call with CFO Schroer, CTO DeRosa and VP Dahlman on April 6 at 2 pm hosted by SunTrust.

ShowHide Related Items >><<
TBIO Translate Bio
$8.89 /

-0.14 (-1.55%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Recommendations
Roth Capital highlights Translate Bio's scalable mRNA platform » 14:40
03/27/20
03/27
14:40
03/27/20
14:40
TBIO

Translate Bio

$10.17 /

-0.04 (-0.39%)

, SNY

Sanofi

$42.74 /

-0.21 (-0.49%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler maintained a Buy rating and $25 price target on Translate Bio (TBIO) following an investor call to discuss Translate and Sanofi's (SNY) mRNA vaccine for COVID-19, where the companies "highlighted the clear outcomes of mRNA vaccine protection in rodents and non-human primates when 'rechallenged'." The analyst added that Translate believes its scalable mRNA platform "can deliver vaccine doses in the hundreds of millions which is essential for an effective pandemic response."

ShowHide Related Items >><<
TBIO Translate Bio
$10.17 /

-0.04 (-0.39%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
SNY Sanofi
$42.74 /

-0.21 (-0.49%)

03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
02/25/20 Evercore ISI
Regeneron upgraded to Outperform after Novartis' 'stumble' at Evercore ISI
Conference/Events
Sanofi to host conference call » 08:19
03/27/20
03/27
08:19
03/27/20
08:19
TBIO

Translate Bio

$10.21 /

+0.27 (+2.72%)

, SNY

Sanofi

$42.95 /

+1.56 (+3.77%)

Conference call to…

Conference call to discuss the joint collaboration between Sanofi and Translate Bio to develop mRNA vaccines for infectious, diseases including COVID-19, will be held on March 27 at 10:30 am. Webcast Link

ShowHide Related Items >><<
TBIO Translate Bio
$10.21 /

+0.27 (+2.72%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
SNY Sanofi
$42.95 /

+1.56 (+3.77%)

03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
02/25/20 Evercore ISI
Regeneron upgraded to Outperform after Novartis' 'stumble' at Evercore ISI
Hot Stocks
Sanofi Pasteur, Translate Bio collaborate to develop COVID-19 vaccine candidate » 05:28
03/27/20
03/27
05:28
03/27/20
05:28
SNY

Sanofi

$42.95 /

+1.56 (+3.77%)

, TBIO

Translate Bio

$10.21 /

+0.27 (+2.72%)

Sanofi Pasteur, the…

Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), and Translate Bio (TBIO) will collaborate to develop a novel mRNA vaccine for COVID-19. This collaboration leverages an existing agreement from 2018 between the two companies to develop mRNA vaccines for infectious diseases. Translate Bio has begun to produce multiple mRNA constructs and will use its mRNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates. Sanofi will provide deep vaccine expertise and support from its external research networks to advance vaccine candidates for potential further development. Translate Bio has established 100 gram single-batch production with its clinical-stage mRNA therapeutics platform. Build-out is underway of dedicated manufacturing space through a contract manufacturing partner to accommodate at least two 250 gram batches per month. Depending on the final human dose, the mRNA platform of Translate Bio has excellent promise to meet the future demands for a pandemic response. For Sanofi, this marks a second collaboration in its efforts to develop a novel COVID-19 vaccine candidate. In February , Sanofi announced a collaboration with the Biomedical Advanced Research and Development Authority, or BARDA, to advance a novel COVID-19 vaccine candidate. The agreement with BARDA calls for Sanofi to initiate development of a recombinant, protein-based vaccine candidate against COVID-19.

ShowHide Related Items >><<
SNY Sanofi
$42.95 /

+1.56 (+3.77%)

03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
02/25/20 Evercore ISI
Regeneron upgraded to Outperform after Novartis' 'stumble' at Evercore ISI
TBIO Translate Bio
$10.21 /

+0.27 (+2.72%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Hot Stocks
Translate Bio's MRT5005 granted Rare Pediatric Disease designation by FDA » 16:37
03/26/20
03/26
16:37
03/26/20
16:37
TBIO

Translate Bio

$10.21 /

+0.27 (+2.72%)

Translate Bio announced…

Translate Bio announced two updates related to its MRT5005 clinical development program in cystic fibrosis or CF. First, the FDA has granted Rare Pediatric Disease designation for MRT5005 for the treatment of CF. MRT5005, the first inhaled mRNA therapeutic, is designed to deliver mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator protein to cells in the lung through nebulization. Also, as the worldwide healthcare system remains focused on the response to the COVID-19 pandemic, the company anticipates related interruptions in enrollment, dosing and follow-up in the ongoing Phase 1/2 clinical trial in patients with CF. The company plans to provide updated timing on the expected interim data readout of the additional single-ascending dose group and the multiple-ascending dose portion of the clinical trial at a later date.MRT5005 is being developed to treat all patients with CF, regardless of the underlying genetic mutation, including those with limited or no CFTR protein. The FDA has granted MRT5005 Orphan Drug, Fast Track and Rare Pediatric Disease designation.

ShowHide Related Items >><<
TBIO Translate Bio
$10.21 /

+0.27 (+2.72%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Syndicate
Translate Bio files $350M mixed securities shelf  16:16
03/13/20
03/13
16:16
03/13/20
16:16
TBIO

Translate Bio

$8.95 /

+0.89 (+11.04%)

 
ShowHide Related Items >><<
TBIO Translate Bio
$8.95 /

+0.89 (+11.04%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Earnings
Translate Bio reports Q4 revenue $3.89M, consensus $3.06M » 16:47
03/12/20
03/12
16:47
03/12/20
16:47
TBIO

Translate Bio

$8.06 /

+0.68 (+9.21%)

"2019 was a year of…

"2019 was a year of important progress for Translate Bio as we reported positive interim data from the single-ascending dose (SAD) portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). We look forward to sharing data from the additional SAD dose group and the multiple-ascending dose (MAD) portion of the trial in the third quarter of this year," said Ronald Renaud, chief executive officer of Translate Bio. "As the first inhaled mRNA therapeutic designed to deliver mRNA coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, MRT5005 has the potential to treat all patients with CF, including those considered non-amenable to currently available CFTR modulator treatments. This first-in-human clinical trial is a critical step towards our goal of addressing that unmet need."

ShowHide Related Items >><<
TBIO Translate Bio
$8.06 /

+0.68 (+9.21%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital
Over a quarter ago
Hot Stocks
Translate Bio receives Fast Track designation for MRT5005 » 07:58
02/26/20
02/26
07:58
02/26/20
07:58
TBIO

Translate Bio

$7.29 /

-0.03 (-0.41%)

Translate Bio announced…

Translate Bio announced that the U.S. Food and Drug Administration has granted Fast Track designation for MRT5005 for the treatment of cystic fibrosis. MRT5005, the first mRNA therapeutic with delivery to the lung, is designed to address the underlying cause of CF, regardless of genetic mutation, by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator protein to cells in the lung through nebulization. The Phase 1/2 clinical trial of MRT5005 is currently ongoing.

ShowHide Related Items >><<
TBIO Translate Bio
$7.29 /

-0.03 (-0.41%)

07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
06/18/19
Fly Intel: Top five analyst initiations
06/18/19 Roth Capital
Translate Bio initiated with a Buy at Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.